WASHINGTON (AP) – The Supreme Court said Friday it will uphold federal rules on the use of abortion drugs, while it takes time to more fully consider issues raised in court challenges.
In an order signed by Justice Samuel Alito, the court asked both sides to consider on Tuesday whether a lower court ruling that limited the Food and Drug Administration’s approval of the drug, mifepristone, should be allowed to take effect when the case is concluded. federal court.
The order expired on Wednesday, indicating that the court will decide on the matter.
The justices are being asked at this point only to determine which part of the April 7 decision by U.S. District Judge Matthew Kacsmaryk in Texas, modified by Wednesday’s appeals decision, can be enforced while the case continues.
The court found itself immersed in a new battle involving abortion less than a year after conservative justices overturned Roe v. Wade and allowed more than a dozen states to effectively ban abortion outright.
President Joe Biden’s administration and New York-based Danco Laboratories, which makes the pill, asked the judges to intervene.
The type of order issued by the court there, remains administrative, usually not an indication of what the judge will do moving forward. It was signed by Alito because he was handling the emergency file from Texas. Alito also authored last year’s opinion that overturned Roe v. Wade.
The Department of Justice and Danco both warned of “regulatory chaos” and harm to women if the high court does not block a lower court ruling that has the effect of tightening FDA rules on where the drug, mifepristone, can be prescribed and distributed.
The new restrictions will take effect on Saturday if the court does not act.
“This application concerns the order of the lower court that has never been against the scientific decision of the FDA and unleashed regulatory chaos by suspending the conditions of use of mifepristone that have been approved by the FDA,” said Attorney General Elizabeth Prelogar, Supreme Court lawyer in the Biden administration, wrote Friday, less than two days. after the appeal decision.
Lawyers for anti-abortion doctors and medical organizations suing for mifepristone said the judge should reject the drug’s and the government’s requests and allow the appeals court-ordered changes to take place.
The Biden and Danco administrations now want a more permanent order that would preserve the current rules while the legal battle over mifepristone continues. As a fallback, they asked the court to take up the issue, listen to arguments and decide in early summer the legal challenge to mifepristone that anti-abortion doctors and medical organizations submitted last year.
Courts rarely act quickly to grant full review of a case before at least one appellate court has fully examined the legal issues.
A ruling by the 5th US Circuit Court of Appeals on Wednesday will prevent the pill, which is used in the most common abortion method, from being delivered or prescribed without a direct visit to a doctor. It would also revoke the Food and Drug Administration’s approval of mifepristone for use beyond the seventh week of pregnancy. The FDA says it is safe for up to 10 weeks.
However, the appeals court did not overturn the FDA’s approval of mifepristone while the fight continued. The 5th Circuit upheld an April 7 ruling by U.S. District Judge Matthew Kacsmaryk, whose far-reaching and almost unprecedented order would have blocked the FDA’s approval of the pill. He gave the administration a week to appeal.
“To the government’s knowledge, this is the first time any court has overturned an FDA condition on drug approval based on disagreement with the agency’s decision on safety — much less done so after the condition has been in effect for years,” Prelogar wrote.
Erin Hawley, a lawyer for the challengers, said in a statement that the FDA has put politics ahead of health concerns in its action on medication abortion.
“The 5th Circuit rightly requires the agency to prioritize women’s health by restoring critical protections, and we will ask the Supreme Court to uphold that responsibility,” said Hawley, senior counsel with the Alliance Defending Freedom, a conservative legal group that also support to overturn Roe v. Wade.
Mifepristone was approved by the FDA more than twenty years ago and is used in combination with another drug, misoprostol.
Adding to the uncertainty, a separate federal judge in Washington on Thursday clarified his own order from last week to clarify that the FDA has done nothing to prevent the availability of mifepristone in 17 Democratic-led states to remain on the market.
It’s unclear how the FDA can comply with the court order in the case, a situation Prelogar described Friday as impossible.
The use of medication abortions increased significantly after the 2016 expansion of FDA rules, according to data collected by the Guttmacher Institute, a research group that supports abortion rights. In 2017, medical abortion caused 39% percent of abortions, but in 2020 it has increased to become the most common method, which is 53% of all abortions.
Experts say the use of medication abortions has increased since the court overturned Roe.
When the drug was first approved, the FDA limited its use to seven weeks during pregnancy. You will also need three private office visits: the first to give you mifepristone, the next to give you a second medication, misoprostol, and the third to treat complications. It also requires a doctor’s supervision and a reporting system for serious side effects of the drug.
If the appeals court’s action is upheld, this will be the condition under which mifepristone can be taken now.
At the heart of the Texas lawsuit are allegations that the FDA’s initial approval of mifepristone was flawed because the agency did not adequately review safety risks.
Mifepristone has been used by millions of women over the past 23 years. While less drastic than completely overturning the drug’s approval, the latest rule still represents a stark challenge for the FDA’s authority to oversee how prescription drugs are used in the US.
Common side effects with mifepristone include cramping, bleeding, nausea, headache and diarrhea. In rare cases, women may experience excessive bleeding that may require surgery to stop.
However, when limiting mifepristone’s ban, FDA regulators cited “very serious incident rates.”
More than 5.6 million women in the US have used the drug by June 2022, according to the FDA. During that time, the agency received 4,200 reports of complications in women, or less than one-tenth of 1% of women taking the drug.
Associated Press writers Paul Weber in Austin, Texas, and Lindsay Whitehurst in Washington contributed to this report.